Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2027-02-20 in 26w | $REGN | Phase 3 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee… NCT07015905 |
| 2027-02-22 in 27w | $REGN | Phase 1 | Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity NCT07594093 |
| 2027-02-26 in 27w | $VRTX | Phase 1 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy… NCT07378865 |
| 2027-02-28 in 28w | $REGN | Phase 3 | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and… NCT07309432 |
| 2027-03-05 in 28w | $VRTX | Phase 1 | A Phase 1, First-in-human Study of VX-433 NCT07584434 |
| 2027-03-12 in 29w | $VRTX | Phase 1 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type… NCT05791201 |
| 2027-03-16 in 30w | $ITCI | Phase 2 | Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized… NCT06480383 |
| 2027-03-22 in 31w | $REGN | Phase 3 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult… NCT06246916 |
| 2027-03-23 in 31w | $VRTX | Phase 1 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in… NCT07437105 |
| 2027-03-25 in 31w | $REGN | Phase 1 | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult… NCT07759167 |
| 2027-03-25 in 31w | $VRTX | Phase 2 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic… NCT06619860 |
| 2027-03-25 in 31w | $REGN | Phase 1 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women… NCT04590326 |
| 2027-03-27 in 31w | $INCY | Phase 1 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic… NCT06818812 |
| 2027-03-31 in 32w | $SRPT | Phase 4 | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With… NCT07542314 |
| 2027-04-05 in 33w | $ITCI | Phase 3 | Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With… NCT05850689 |
| 2027-04-06 in 33w | $VRTX | Phase 3 | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term… NCT05331183 |
| 2027-04-06 in 33w | $VRTX | Phase 3 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With… NCT07231419 |
| 2027-04-12 in 34w | $ZEAL | Phase 1 | Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function NCT07682818 |
| 2027-04-13 in 34w | $INCY | Phase 1 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When… NCT07559474 |
| 2027-04-13 in 34w | $AMGN | Phase 2 | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum… NCT05549258 |
| 2027-04-14 in 34w | $BMRN | Phase 1 | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and… NCT06280209 |
| 2027-04-19 in 35w | $AMGN | Phase 3 | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) NCT06700343 |
| 2027-04-24 in 35w | $REGN | Phase 4 | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting… NCT06572228 |
| 2027-04-27 in 36w | $INCY | Phase 2 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer… NCT07023627 |
| 2027-04-27 in 36w | $AMGN | Phase 3 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan… NCT06987695 |